Opes Wealth Management LLC Sells 5,201 Shares of Johnson & Johnson $JNJ

19 Mar 2026, 06:31 by Renee Jackson · The Cerbat Gem

Opes Wealth Management LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 42.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,968 shares of the company’s stock after selling 5,201 shares during the period. Opes Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,292,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. AustralianSuper Pty Ltd boosted its position in shares of Johnson & Johnson by 632.0% during the third quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock valued at $16,536,000 after buying an additional 77,000 shares during the last quarter. J.W. Cole Advisors Inc. raised its position in Johnson & Johnson by 2.2% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock valued at $24,278,000 after buying an additional 2,769 shares during the last quarter. Guinness Asset Management LTD raised its position in Johnson & Johnson by 0.4% in the 3rd quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after buying an additional 5,994 shares during the last quarter. Treasurer of the State of North Carolina lifted its stake in Johnson & Johnson by 8.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after acquiring an additional 94,957 shares in the last quarter. Finally, National Pension Service boosted its holdings in Johnson & Johnson by 3.2% during the 3rd quarter. National Pension Service now owns 4,926,569 shares of the company’s stock worth $913,484,000 after acquiring an additional 151,707 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares in the company, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on JNJ. Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a report on Friday, January 23rd. Rothschild & Co Redburn boosted their price target on shares of Johnson & Johnson from $180.00 to $210.00 and gave the stock a “neutral” rating in a report on Thursday, February 19th. Barclays increased their price objective on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a research report on Thursday, January 22nd. Finally, Bank of America reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $236.17.

Get Our Latest Stock Report on JNJ

Johnson & Johnson Stock Down 0.4%

Shares of NYSE JNJ opened at $237.15 on Thursday. The business’s fifty day moving average price is $233.95 and its 200-day moving average price is $207.76. Johnson & Johnson has a one year low of $141.50 and a one year high of $251.71. The stock has a market capitalization of $571.21 billion, a PE ratio of 21.46, a P/E/G ratio of 2.35 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The business had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: FDA approves ICOTYDE (icotrokinra), J&J’s once‑daily oral IL‑23R targeted peptide for moderate‑to‑severe plaque psoriasis — a first‑in‑class oral alternative to leading injectable IL‑23 therapies that could expand patient access and drive new prescription revenue. US FDA approves J&J’s oral psoriasis pill
Positive Sentiment: HSBC raised its JNJ price target to $280 (from $265) and reiterated a Buy, citing healthcare strength and likely improved near‑term fundamentals — this adds analyst support and gives upside cushion relative to current levels. HSBC Sees Healthcare Strength, Lifts Johnson & Johnson (JNJ) Price Target
Neutral Sentiment: Analyst commentary and comparisons (e.g., J&J vs Merck) highlight relative strengths/risks across pipelines and cash flows — useful context but not an immediate catalyst. J&J or Merck? Key Factors Investors Must Weigh Right Now
Neutral Sentiment: Market watchlists and “stocks to watch” mentions raise visibility but don’t change fundamentals immediately. 4 stocks to watch on Wednesday: T, M, MU, JNJ
Negative Sentiment: Shares recently pulled back (reports of a slide and lower intraday volume) indicating short‑term profit‑taking despite the positive drug news and analyst upgrade; that pressure likely explains the stock trading down today. Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.